Skip to content
Open access

Association of Caudal-Type Homeobox 2 Immunohistochemical Expression With Pathological Stage, Tumor Grade, and Histological Subtype in Colorectal Malignancies: A Single-Center Observational Study

Oct 2026 · Cureus · Vol 18 · 0 citations · 19 references
Medicine

TL;DR

Findings support CDX2 as a practical adjunct marker of adverse tumor biology in colorectal malignancies rather than independent survival prognostication and support clinicopathological prognostic association rather than independent survival prognostication.

Abstract

Background Caudal-type homeobox 2 (CDX2) is a nuclear transcription factor that maintains intestinal epithelial differentiation. Reduced CDX2 expression has been associated with adverse pathological features and inferior outcomes in colorectal cancer, but its clinicopathological value depends on the scoring method and tumor context. Methods This single-center observational study evaluated 50 histopathologically confirmed colorectal malignancies. CDX2 immunohistochemistry was scored semi-quantitatively by multiplying nuclear staining proportion (0-4) by staining intensity (0-3), yielding an immunoreactivity score (IRS) of 0-12. Low/reduced expression was defined as IRS ≤4 and high/preserved expression as IRS ≥5. The patient-level master chart was used to summarize IRS and its associations with stage and grade; the histology comparison retained the original aggregated subtype counts. Exact tests used evaluable cases; pooled stage/grade analyses were exploratory, and subtype analysis was limited to major adenocarcinomas. The primary analytical endpoint was the association between CDX2 expression and pathological stage. The original pathology records for six cases recorded as pTis with N1/N2 disease were rechecked, and a conservative sensitivity analysis excluding these records was performed. Results CDX2 was evaluable in 48 of 50 cases; 29/48 (60.4%) showed low expression and 19/48 (39.6%) showed high expression. Median IRS was 2 (range 0-12). Among 43 cases with complete stage information and evaluable CDX2, low expression increased from 44.4% in stage 0, 30.0% in stage I, and 40.0% in stage II to 83.3% in stage III and 100% in the single stage IV case (Fisher-Freeman-Halton p=0.023). Advanced stage was associated with higher odds of low CDX2 expression (odds ratio (OR) 8.89, 95% confidence interval (CI) 2.01-39.22; p=0.004), although the wide confidence interval indicates imprecision. All 19 high-grade tumors showed low CDX2, compared with 9/27 (33.3%) low-grade tumors and 1/2 (50.0%) intermediate-grade tumors (p<0.001). Low CDX2 was also more frequent in mucinous adenocarcinoma (8/10, 80.0%) and signet-ring cell carcinoma (5/5, 100%) than in conventional adenocarcinoma (10/22, 45.5%; p=0.026). Pathology records confirmed that six entries combined primary lesions documented as pTis with separately submitted regional lymph nodes containing metastatic tumor. In a conservative sensitivity analysis excluding these six records, the early-versus-advanced-stage association persisted (low CDX2: 10/13 (76.9%) versus 9/24 (37.5%); OR 5.56, 95% CI 1.20-25.71; two-sided Fisher’s exact p=0.038), whereas the overall five-stage association is not statistically significant (exact p=0.182). Conclusion Reduced CDX2 expression tracked closely with advanced pathological stage, high tumor grade, and aggressive adenocarcinoma morphology. These findings support CDX2 as a practical adjunct marker of adverse tumor biology in colorectal malignancies. Because survival, recurrence, and molecular profiling were not evaluated, the present study supports clinicopathological prognostic association rather than independent survival prognostication. Because the cohort included different tumor classes and the detailed five-stage result was sensitive to the handling of six nonstandard pTis/node-positive records, the stage and grade findings should be considered exploratory.

Read PDF

Similar papers

Open access Oct 2026

HOXB13 immunohistochemical expression in prostate cancer and its association with tumor grade and invasiveness at a tertiary Referral Hospital in Western Kenya

Prostate cancer remains an important health burden in Kenya, where delayed diagnosis and presentation with advanced disease complicate risk stratification. This study evaluated HOXB13 immunohistochemical expression in archived prostate cancer biopsies and examined its relationship with histopathological grade, patholog...

Dauglas Muchika, Gladys Essendi Chunge, Sarah Mombua Kilungya et al. · 0 citations
Open access Oct 2026

Frequent PRAME Expression in Ameloblastoma: Immunohistochemical Profiling, Clinicopathologic Correlations, and Interobserver Reproducibility in a 37-Case Cohort

Ameloblastoma is a histologically benign odontogenic epithelial tumor with locally destructive growth and a clinically relevant risk of recurrence. Established molecular research has been largely focused on MAPK-pathway alterations, whereas markers capturing other dimensions of tumor biology remain limited. Preferentia...

Fedor Popovic, D. Spasić, Novica Boricic et al. · 0 citations
Open access Nov 2026

TROP-2 Expression and Complex Glandular Pattern in Resected Pancreatic Ductal Adenocarcinoma: An Exploratory Clinicopathological Study

This study aimed to evaluate TROP-2 immunoexpression and complex glandular pattern (CGP) in resected pancreatic ductal adenocarcinoma (PDAC) and to investigate their associations with clinicopathological and histopathological features and survival outcomes. This retrospective study included 73 treatment-naïve patients...

Pelin Seçken, Hale Kıvrak, G. Keski̇n et al. · 0 citations
Open access Nov 2026

HER2 expression and clinicopathological correlates across immunohistochemical phenotypes of urothelial carcinoma: a retrospective single-center study

Human epidermal growth factor receptor 2 (HER2) is a treatment target in urothelial carcinoma (UC), but the features of tumors with HER2 overexpression are not well defined. This study evaluated the clinicopathological factors related to HER2 expression and compared its frequency and tumor characteristics among imm...

Yang Peng, Yong-Jia Zhang, Guang-Lei Miao et al. · 0 citations
Open access Oct 2026

Programmed Death Ligand-1 (PD-L1) Expression in Endometrial Carcinoma: An Immunohistochemical Study and Correlation with Clinicopathological Parameters

Endometrial carcinoma (EC) is among the most prevalent gynecological malignancies worldwide, with increasing incidence linked to obesity and aging populations. Programmed death-ligand 1 (PD-L1) plays a crucial role in tumor immune evasion by interacting with PD-1, and its expression has been implicated in the aggressiv...

Rohan Bhavthankar, D. Fonseca, S. Murthy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.